COVID 19 in Antimicrobial and Antibacterial Agents
COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally Bacterial co-infections are correlated with unfavorable outcomes in respiratory viral infections. Despite, microbiological and antibiotic data related to COVID-19 are skimpy, competent use of antibiotics in line with antibiotic stewardship (ABS) principles is guaranteed during the pandemic. Bacterial and fungal co-infections are subtle in COVID-19 patients and are mainly ubiquitous in critically ill patients. In addition, studies are needed to estimate the impact of antimicrobial therapy on therapeutic outcomes in COVID-19 patients to prevent antimicrobial overuse. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was consequently identified as the causative pathogen. Ordinarily, respiratory viral infections are a risk factor for bacterial co-infections, which then increase disease austerity and mortality. It has been established that sepsis and ventilator-associated pneumonia are frequently observed complications in COVID-19 patients.
Related Conference of COVID 19 in Antimicrobial and Antibacterial Agents
7th International Conference on Vaccines, Immunology and Clinical Trials
COVID 19 in Antimicrobial and Antibacterial Agents Conference Speakers
Recommended Sessions
- Antibiotics, Antimicrobial & Chemotherapy
- Antimicrobial Pathogens : Alternative Approaches
- Antimicrobials
- Antimicrobiology in Epidemiology
- COVID 19 in Antimicrobial and Antibacterial Agents
- Global Spread of Viruses
- Immunity , Infection Diseases and Agents
- Microbial Immunology
- Microbial Physiology and Metabolism
- Microorganisms in Recent Drug Discovery
- Pharmaceutical microbiology
- Pharmalogical Consideration of Infectious Disease and Agents
- Vaccine and Vaccination
- Vaccines and Therapeutics
Related Journals
Are you interested in
- Animal & Plant Derived Vaccines - Vaccine Immunology 2024 (France)
- Animal Models & Clinical Trials - Vaccine Immunology 2024 (France)
- Antibodies: Engineering & Therapeutics - Vaccine Immunology 2024 (France)
- Antiviral Therapies - Virology 2024 (Austria)
- Basic Immunology - Virology 2024 (Austria)
- Cancer, Malaria & TB Vaccines - Vaccine Immunology 2024 (France)
- Cellular Immunology & Latest Innovations - Vaccine Immunology 2024 (France)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Clinical Immunology - Virology 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- Combination & Conjugate Vaccines - Vaccine Immunology 2024 (France)
- COVID19 Vaccines - VACCINE CONGRESS 2024 (Spain)
- Current Research & Future Challenges - Vaccine Immunology 2024 (France)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- DNA & Synthetic Vaccines - Vaccine Immunology 2024 (France)
- Emerging Infectious Diseases and Global Health - VACCINES WORLD 2024 (Canada)
- Emerging Viral Diseases - Virology 2024 (Austria)
- Epidemiology and Public Health - Virology 2024 (Austria)
- Ethical and Societal Aspects of Vaccination - VACCINES WORLD 2024 (Canada)
- Fish & Poultry Vaccines - Vaccine Immunology 2024 (France)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- Geriatric Immunization - Vaccine Immunology 2024 (France)
- Geriatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Global Vaccine Access - VACCINE CONGRESS 2024 (Spain)
- HIV Vaccines - Vaccine Immunology 2024 (France)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunization in Special Populations - VACCINES WORLD 2024 (Canada)
- Immunodiagnostics and Monitoring Immune Responses - VACCINES WORLD 2024 (Canada)
- Immunogenetics and Genomics - Virology 2024 (Austria)
- Immunogenetics and Personalized Vaccinology - VACCINES WORLD 2024 (Canada)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunology of Vaccines - VACCINE CONGRESS 2024 (Spain)
- Immunometabolism - Virology 2024 (Austria)
- Immunopathology and Host-Pathogen Interactions - VACCINES WORLD 2024 (Canada)
- Immunotherapy - Virology 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology 2024 (Austria)
- Inflammation and Immune Response - Virology 2024 (Austria)
- Innate and Adaptive Immune Responses - VACCINES WORLD 2024 (Canada)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- Innovative Immunotherapies - VACCINES WORLD 2024 (Canada)
- Next Generation Vaccines - VACCINE CONGRESS 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Novel Vaccine Platforms - VACCINE CONGRESS 2024 (Spain)
- One Health Approach - VACCINE CONGRESS 2024 (Spain)
- Paediatric Vaccination - Vaccine Immunology 2024 (France)
- Paediatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Public Health and Vaccination Programs - VACCINES WORLD 2024 (Canada)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Travel & Edible Vaccines - Vaccine Immunology 2024 (France)
- Vaccination Strategies for Vector-Borne Diseases - VACCINES WORLD 2024 (Canada)
- Vaccine Adjuvants - VACCINE CONGRESS 2024 (Spain)
- Vaccine Clinical Trials - VACCINE CONGRESS 2024 (Spain)
- Vaccine Delivery Systems - VACCINE CONGRESS 2024 (Spain)
- Vaccine Development - Virology 2024 (Austria)
- Vaccine Development and Design - VACCINES WORLD 2024 (Canada)
- Vaccine Development for Emerging Diseases - VACCINE CONGRESS 2024 (Spain)
- Vaccine Economics and Market Access - VACCINES WORLD 2024 (Canada)
- Vaccine Education and Advocacy - VACCINES WORLD 2024 (Canada)
- Vaccine Equity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Financing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Immunogenicity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Manufacturing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Policy and Regulation - VACCINE CONGRESS 2024 (Spain)
- Vaccine Production & Development - Vaccine Immunology 2024 (France)
- Vaccine Safety - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety and Adverse Event Monitoring - VACCINES WORLD 2024 (Canada)
- Vaccine Surveillance - VACCINE CONGRESS 2024 (Spain)
- Vaccines - Vaccine Immunology 2024 (France)
- Vaccines & Autism - Vaccine Immunology 2024 (France)
- Vaccines against Drugs - Vaccine Immunology 2024 (France)
- Vaccines against Infectious Diseases - Vaccine Immunology 2024 (France)
- Vaccines Epidemiology - VACCINE CONGRESS 2024 (Spain)
- Vaccines for Immune Mediated Diseases - Vaccine Immunology 2024 (France)
- Vaccines for Non-Communicable Diseases - VACCINES WORLD 2024 (Canada)
- Vaccines for Pregnant Women & Neonates - Vaccine Immunology 2024 (France)
- Vaccines for Unconventional Diseases - Vaccine Immunology 2024 (France)
- Vaccines Immunology - VACCINE CONGRESS 2024 (Spain)
- Vectors, Adjuvants & Delivery Systems - Vaccine Immunology 2024 (France)
- Viral Diagnostics - Virology 2024 (Austria)
- Viral Genomics and Evolution - Virology 2024 (Austria)
- Viral Immunology - Virology 2024 (Austria)
- Viral Pathogenesis - Virology 2024 (Austria)
- Viral Vaccines - Virology 2024 (Austria)